CORRECTION article

Front. Oncol., 29 March 2022

Sec. Molecular and Cellular Oncology

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.819908

Corrigendum: LncRNA DCST1-AS1 Promotes Endometrial Cancer Progression by Modulating the MiR- 665/HOXB5 and MiR-873-5p/CADM1 Pathways

  • 1. Gynaecology Clinic, People’s Hospital of Rizhao, Rizhao, China

  • 2. No. 2 Department of Gynaecology, People’s Hospital of Rizhao, Rizhao, China

  • 3. Reproductive Medicine Center, Maternal and Child Health Hospital of Rizhao, Rizhao, China

  • 4. No. 2 Department of Gynaecology, Baiqiuen Hospital of Rizhao, Rizhao, China

Article metrics

View details

2

Citations

1,2k

Views

895

Downloads

In the original article, Changjiang Lei was designated as one of the authors. Changjiang Lei has now been removed from the author list. The corrected Author Contributions Statement appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Author contributions

PS and JW designed and conducted the experiments. HT, LL, HG, and XW analyzed the data. JW wrote the manuscript and PS revised the manuscript. All authors contributed to the article and approved the submitted version.

Summary

Keywords

endometrial cancer, long noncoding RNA, DC-STAMP domain-containing 1-antisense 1, microRNA-665, homeobox B5, microRNA-873-5p, cell adhesion molecule 1

Citation

Wang J, Shi P, Teng H, Lu L, Guo H and Wang X (2022) Corrigendum: LncRNA DCST1-AS1 Promotes Endometrial Cancer Progression by Modulating the MiR- 665/HOXB5 and MiR-873-5p/CADM1 Pathways. Front. Oncol. 12:819908. doi: 10.3389/fonc.2022.819908

Received

22 November 2021

Accepted

04 March 2022

Published

29 March 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

12 - 2022

Updates

Copyright

*Correspondence: Pingping Shi,

†These authors have contributed equally to this work

This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics